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Abbreviations 
BH: Benjamini-Hochberg 
conA: concanamycin A 
GFP: green fluorescent protein 
IAV: influenza A virus 
IF: immunofluorescence 
LC: liquid chromatography 
MS: mass spectrometry 
MOI: multiplicity of infection 
PAMP: pathogen-associated molecular pattern 
PFU: plaque-forming unit 
SILAC: stable isotope labelling by amino acids in cell culture 
vRNPs: viral ribonucleoprotein complexes  
WB: western blot  
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Summary 
Seasonal epidemics of influenza A virus in the human population are a major cause of severe 
illness and are of high socio-economic relevance. For the design of effective anti-viral therapies, 
a detailed knowledge of cellular pathways perturbed by virus infection is critical. We performed 
comprehensive expression and organellar proteomics experiments to identify new protein targets 
and cellular pathways affected by influenza A virus. Type I as well as type II interferon pathways 
were upregulated upon infection, affecting amongst others poly ADP-ribose polymerase 
transcription factors and ubiquitin-like modifiers. Interestingly, influenza A virus had also a major 
influence on the subcellular localization of proteins and complexes. In virus-infected cells, the 
vesicular compartment appeared expanded and in particular, the composition of autophagsomes 
was altered by targeting of ribosomes to these vesicular organelles, next to viral mRNA. Thus, 
autophagy may support viral protein translation by clustering of the critical cellular components. 
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Introduction 
Influenza virus infections of the human respiratory tract are a major cause of morbidity and 
mortality (1). Seasonal epidemics mainly affect young, elderly, or chronically ill people and are 
estimated to result in up to 5 million cases of severe illness, including up to 500`000 fatal outcomes 
(1). In addition to the annual outbreaks, the rarely occurring influenza A virus (IAV) pandemics, 
such as the “Spanish Flu” in 1918-1919, gave rise to tens of millions of deaths worldwide (2). 
Periodic influenza epidemics occur as a result of an accumulation of mutations in the viral surface 
protein hemagglutinin of influenza viruses circulating in the human population to escape the 
humoral immune response. IAV reassortant viruses, harboring a “new” hemagglutinin where no 
preexisting immunity exist, may cause pandemics. 
Due to the high mutation rates of viral RNA, therapies based on anti-viral drugs targeting virally 
encoded proteins themselves have likely only limited effects (3). Hence, understanding of the host 
factors critical for viral replication is regarded as a powerful alternative to characterize new target 
processes accessible for interference with viral replication. Several genome-wide RNAi screens 
were performed to identify host factors necessary for IAV replication (4-6). In parallel, global mass 
spectrometry (MS)-based proteomics studies were also performed to identify such factors. These 
analyses focused either on the identification and characterization of host-virus protein interactions 
(7,8), or on the analyses of IAV-induced changes in host protein abundances (9-11). In the current 
study, we aimed at comprehensively characterizing IAV-induced changes in the host cell proteome 
by not only quantifying differences in protein abundances, but also by characterizing the dynamic, 
IAV-induced regulation of the subcellular localization of proteins complexes. 
During its replication cycle, IAV modifies and hijacks numerous processes and cell organelles. 
After endocytic cell entry, viral ribonucleoprotein complexes (vRNPs) are released into the 
cytoplasm and enter the nucleus where viral mRNA synthesis and replication occurs (12,13). A 
cell process utilized by IAV that has recently attracted attention is autophagy, a catabolic recycling 
process that targets organelles and multiprotein complexes for lysosomal degradation (14). IAV 
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blocks the maturation of autophagosomes (15), which are double membrane vesicles that shuttle 
intracellular cargo to lysosomes. The autophagic membranes are further redirected to the plasma 
membrane to enable the release of viral particles with increased stability (16).  
Here, we present expression proteomics and organellar proteomics data, highlighting the 
multifaceted influences of IAV on human proteome composition and configuration. We 
characterize signaling pathways and new molecular players regulated by IAV infection and 
analyze the cellular redistribution of host protein complexes. Specifically, we study the impact of 
IAV on the vesicular proteome, mainly autophagosomes, highlighting a potential new role of these 
organelles in virus replication. 
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Experimental Procedures 
 
Cells and culture conditions 
Adherent human A549 were cultured and passaged in high glucose DMEM (PAA Laboratories 
GmbH, Coelbe, Germany), supplemented with 10% FBS, 1% Penicillin/Streptomycin and 1% L-
glutamine. For SILAC-labeling, cells were grown in SILAC-DMEM (high glucose) (Thermo-Fisher 
scientific, Langenselbold, Germany), supplemented with 10% dialyzed FBS (Invitrogen, 
Darmstadt, Germany), 1% Penicillin/Streptomycin and 1% L-glutamine, containing a final 
concentration of 42 mg/l L-arginine HCl, 73 mg/l L-lysine HCl and 1.33 mg/l L-proline for light 
labeling (Sigma-Aldrich, Taufenkirchen, Germany), L-arginine-13C614N4 and L-lysine-2H4 (Arg6, 
Lys4) and 1.33 mg/l L-proline for medium heavy, or L-arginine-13C6-15N4 and L-lysine-13C615N2 
(Arg10, Lys8) and 1.33 mg/l L-proline for heavy labeling (Silantes, München, Germany). To gain 
full incorporation of labeled amino acids, cells were cultured for at least 5 cell doublings in the 
corresponding label. For harvesting, cells were washed 3 times with ice cold DPBS, collected with 
a cell scraper, centrifuged at 1000 g for 5 min and cell pellets were stored at -80°C until use. 
 
Experimental Design and Statistical Rationale 
We minimally analyzed two biological replicates from all conditions and correlations of respective 
data are shown in the supplemental information. Values of biological replicates were combined as 
average and log2 transformed to generate normal distributions. All statistical tests were corrected 
for multiple testing as outlined in the respective paragraphs. 
 
IAV infection 
Cells (60-70% confluence) were washed twice with RPMI (PAA Laboratories) and incubated with 
influenza virus strain X:31 A/AICHI/68 (Charles River, Wilmington MA; Batch: 4XAP091028) in 
RPMI at a multiplicity of infection (MOI) of 2 PFU per cell (for IF staining a MOI of 4 was used) for 
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1h at 37°C with 5% CO2. Cells were washed once with DPBS and incubated with complete DMEM 
(high glucose) for 24 hours. 
 
Cell fractionation 
Cell pellets were solved in homogenization medium (HM; 0.25 M Sucrose, 1 mM EDTA, 20 mM 
HEPES-NaOH pH 7.4), containing protease inhibitor (Complete protease inhibitor cocktail, Roche 
Diagnostics GmbH, Mannheim, Germany). The solution was dounced 150 times followed by 
several centrifugation steps to collect nuclear (1,000 g), mitochondrial (3,000 g) and vesicular 
fractions (17,000 g). The supernatant after the last centrifugation was collected as the cytosolic 
fraction. All pellets were resuspended in HM and centrifuged for a second time at the respective 
speed. 
The mitochondrial and vesicular fractions were resuspended in modified RIPA buffer (1% NP-40, 
150 mM NaCl, 50 mM Tris pH 7.5, 0.25% Na-deoxycholate) and incubated on ice for 10 min 
followed by a centrifugation for 10 min at 17,000 g at 4°C. 
The nuclear pellet was solved in 3 ml of S1 (0.25 M Sucrose, 10 mM MgCl2). This solution was 
layered over 3 ml of S2 (0.35 M Sucrose, 0.5 mM MgCl2), and passed through at 1,430 g for 5 min 
at 4°C. The pellet was again solved in 3 ml S1 and the first step was repeated. The nuclear pellet 
was solved in modified RIPA buffer and the nuclei were opened by sonification (3x 30 sec with 
50% intensity in an ultrasonic bath, kept at ice in between), followed by a centrifugation at 3,000 
g for 10 min at 4°C. The supernatant contains the nucleoplasmic fraction. The protein amount of 
all collected fractions was determined (BCA Protein Assay kit, PierceR, Thermo-Fisher scientific) 
according to the manufacturer`s protocol, adjusted and the fractions were further processed for 
MS or western blot. 
 
Autophagosome purification by protein correlation profiling 
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Cell pellets were treated as outlined above. The 17,000 g pellet containing the vesicular fraction 
was resuspended in 1 ml HM and loaded on top of an iodixanol gradient (Sigma Aldrich). The 
gradient was made of five 1.6 ml gradient steps (5, 10, 16, 24 and 30% iodixanol in HM), prepared 
by underlying layers with higher density solutions in 12 ml centrifugation tubes. Vesicles were 
separated on the gradient for 17 h at 100,000 g at 6 °C in a swing out rotor. Fractions of 1 ml were 
collected, diluted with 1 ml HM and centrifugated at 4°C for 20 min at 40,000 g in a fixed angle 
rotor. Pellets were solved in 25 µl SDS-PAGE loading buffer and further processed for MS or 
western blot (17). 
 
Protease protection assay 
The vesicular fraction, gained by differential centrifugation was used to perform the protease 
protection assay. The vesicular pellet was solved in HM and split into 5 tubes. One sample was 
left untreated, two were treated with 40 µg/ml and 80 µg/ml proteinase K respectively and two 
were treated with 0.2% triton and 40 µg/ml and 80 µg/ml proteinase K, respectively. Samples were 
vortexed and incubated for 30 min on ice. 7% TFA was used in order to stop the enzyme activity. 
The precipitated proteins were pelleted via centrifugation for 10 min at 4°C at 21`100 g and 
washed twice with acetone. 1 x SDS-loading buffer containing 1 mM DTT was added and the 
samples were brought into solution by heating them up to 65°C for 30 minutes. 
 
Western blot 
Samples were mixed with SDS-PAGE loading buffer with 1 mM DTT and incubated for 10 min at 
95°C. After that, proteins were separated on SDS-PAGE on self-casted SDS-gels (dependent on 
protein size, gels between 7.5% and 12.5% were used) and transferred onto a nitrocellulose 
membrane. The membranes were blocked with 5% milk powder in 1x TBS with 0.1% Tween-20 
for 1 h at room temperature and incubated for 1 h at room temperature or overnight at 4°C with 
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primary antibodies. HRP-coupled secondary antibodies and a chemiluminescent detection assay 
were used for visualization according to manufacturer`s instructions. 
Following primary antibodies were used. Santa Cruz Biotechnology, Inc., Heidelberg, Germany: 
Anti-beta-actin (sc-47778), Anti-DTX3L (sc-100627), Anti-EEA1 (G-4, sc-137130), Anti-GFP (B-2, 
sc-9996), Anti-Influenza A NS1 (NS1-23-1, sc-130568), Anti-PARP14 (sc-377150), Anti-
Ribosomal Protein L4 (RQ-7, sc-100838), Anti-Tom20 (F-10, sc-17764), Anti-UBC8 (sc-135629). 
Abcam, Cambridge, United Kingdom: Anti-beta-tubulin (ab6046), Anti-MCM7 (47DC141). Roche: 
Anti-HA (11867423001). Cell Signaling Technology, Inc., Danvers, MA, USA: Anti-Lamin A/C 
(2032), Anti-LC3 A/B (4108). Biomol: Anti-p62/SQSTM1 (PW 986). Merck, Darmstadt, Germany: 
Anti-GAPDH (MAB374). 
Following secondary antibodies were used. Thermo-Fisher Scientific: Alexa fluor 488 (A21042), 
Alexa fluor 488 (A21206), Alexa fluor 568 (A11011), Alexa fluor 568 (A10037). GE Healthcare, 
München, Germany: Anti-rabbit HRP (NA934V), Anti-mouse HRP (NXA931). Dianova GmbH, 
Hamburg, Germany: Anti-rat HRP (112-035-062). 
 
Calculation of autophagic flux 
The intensity gained by western blot was measured using imageJ analysis software and the level 
of LC3-II was normalized to GAPDH as a loading control. Autophagic flux was calculated as 
intensity of LC3-II with conA divided by intensity of LC3-II without conA. The additional 
accumulation of LC3-II under conA treatment with infection (conA+FluA) was compared to the 
level of infection (FluA) only. The same was done for conA only treated cells compared to 
untreated control cells. The level of conA /untreated was set to 100% and the (conA+FluA)/FluA 
was adjusted accordingly.  
 
Immunofluorescence staining 
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For indirect immunofluorescence staining, A549 cells were grown on coverslips, fixed with 4% 
PFA and blocked with 1% BSA in PBS for 30 min at room temperature. Incubation with primary 
antibodies diluted in 1% BSA in PBS was performed for 1 h at room temperature or overnight at 
4°C. After incubation with the fluorophore-coupled secondary antibody in 1% BSA in PBS for 1 h, 
the samples were embedded in fluorescence mounting medium, containing DAPI. Pictures were 
taken with an IF microscope. 
 
RNA purification, cDNA synthesis and PCR conditions 
For RNA purification, cell pellets or pellets of the vesicular fraction after gradient centrifugation 
were extracted with the RNeasy Mini kit following the manufacturer`s instructions using the RLT 
buffer. Dependent on the experiments, 1 µg of total RNA was reverse transcribed using the First 
Strand cDNA Synthesis Kit with random hexamer primers. PCR primer : M1, 
ATGAGTCTTCTAACCGAGG, TCACTTGAACCGTTGCATC ; NS1, 
ATGGATCCAAACACTGTGTC, TCAAACTTCTGACCTAATTGTT. 
 
MS sample preparation 
Samples were lysed in SDS-PAGE loading buffer, reduced with 1 mM DTT for 10 min at 95°C and 
alkylated using 5.5 mM iodacetamide for 30 min at 25°C in the dark. Proteins were separated by 
SDS-PAGE using 4-12% Bis-Tris gels (NuPAGE, Invitrogen, Darmstadt, Germany). Staining with 
Colloidal Blue was used to visualize the proteins. The gel lanes were cut into 10 slices of equal 
size, which were cut into small cubes. Remaining Colloidal Blue was washed out by incubation 
with ABC buffer (100 mM ammonium bicarbonate pH 7.5) for 10 min followed by incubation for 10 
min in ethanol. This was repeated for three times. 12.5 ng/µl trypsin (MS grade, Promega, 
Mannheim, Germany) was added and incubated for digestion over night at 37°C. Trypsin activity 
was stopped by acidification with 0.5% TFA. Remaining peptides were washed out of the gel 
cubes by two times incubation in 100 µl ethanol and the supernatant of the respective slice was 
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combined. The peptide solution was concentrated to less than 50 µl in a speedvac to remove 
ethanol. Samples were desalted on STAGE tips (18). 
 
Mass spectrometry 
Samples were fractionated by nanoscale HPLC on either a 1200 (Agilent Technologies; 
Waldbronn, Germany) or a NanoLC Ultra (Eksigent, AB SCIEX, Redwood City, CA, USA) 
connected online to a LTQ Orbitrap XL mass spectrometer (Thermo Fisher Scientific, Bremen, 
Germany). Fused silica HPLC-column tips with 75 µm inner diameter were self-packed with 
Reprosil–Pur 120 ODS–3 (Dr. Maisch, Ammerbuch, Germany) to a length of 20 cm. Samples were 
directly injected into the mass spectrometer by applying a linear gradient from 10–30% acetonitrile 
in 0.5% acetic acid with a flow rate of 250 nl/min and for sample application 500 nl/min. The spray 
voltage was set to 2.3 kV and the ion-transfer tube had a temperature of 125°C. All full-scan were 
recorded in the Orbitrap in the range from m/z 370 to 2,000 and at resolution 60,000. MS/MS 
scans were recorded in the linear ion trap and the top5 method was applied. The normalized 
collision energy was set to 35% at a target value of 5,000. Singly charged and ions with 
unassigned charge state were excluded from MS/MS. 
 
Identification of proteins and protein ratio assignment using MaxQuant 
The MS raw data files were uploaded into the MaxQuant software (version 1.2.2.5, 1.3.0.5) (19). 
Database searches were performed against a homemade full-length human database containing 
common contaminants such as keratins and enzymes used for in–gel digestion as well as IAV 
protein sequences (87`093 entries). Carbamidomethylcysteine was set as fixed modification, 
oxidation of methionine and protein amino–terminal acetylation was set as variable modifications. 
Dependent on the experiment, double or triple SILAC was used as quantitation mode. The enzyme 
specificity was trypsin/P+DP with three allowed miss cleavages. The MS/MS tolerance was set to 
0.5 Da and the mass precision of identified peptides after recalibration was in general less than 1 
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ppm. For identification and quantitation, the following settings were used: peptide and protein FDR 
were set to 0.01, maximum peptide posterior error probability (PEP) was set to 0.1, minimum 
peptide length was set to 7, minimum number peptides for identification and quantitation of 
proteins was set to two of which one must be unique, minimum ratio count was set to two, and 
only unmodified peptides and the variable modification were used for protein quantification. The 
“match between run” option was used with a time window of 2 min. 
MS raw data have been deposited to the ProteomeXchange Consortium via the PRIDE partner 
repository (20). Project Name: Influenza A virus induces autophagosomal targeting of ribosomal 
proteins; Project accession: PXD007809; Reviewer account details: Username: 
reviewer13476@ebi.ac.uk; Password: PuVBwX6A 
 
Data analysis 
For clustering of data, all proteins with ratios in all six gradient fractions or in all four compartments 
were used to generate respective distribution profiles by applying the fuzzy c-means clustering 
(21) using R 2.8.1 or GProX (22). To address the biological implications of the proteins in each 
cluster, Biological Process and Molecular Function GO terms were retrieved using Perseus (23). 
A Fisher`s exact test was performed to identify enriched GO terms in the corresponding cluster, 
compared to the background of the same sample over all cluster. A Benjamini-Hochberg FDR 
below 0.01, an enrichment factor of 2 and a membership of at least five per GO term in the cluster 
were required to regard the enrichment as significant. Additionally, all proteins of a cluster were 
tested for known and predicted interactions by using STRING (24). Cytoscape was used for 
visualization and network analysis (25). 
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Results 
 
Characterization of IAV-induced changes in the composition of the host cell proteome 
To determine the effect of IAV infection on the composition of the host cell proteome, we chose a 
quantitative expression proteomics approach based on SILAC labeling, analyzing both, whole cell 
lysate (WCL) as well as major organelle fractions to achieve a deep proteomic coverage (Figure 
1A). Briefly, A549 human lung epithelial carcinoma cells were differentially SILAC labeled and 
either left untreated as control or infected for 24 h with IAV strain X:31 (A/AICHI/68) with an MOI 
of 2. WCL, nuclear, mitochondrial, vesicular and cytosolic cell fractions were mixed 1:1, 
respectively, and analyzed as outlined (Figure 1A, Supplemental Figure S1). In two biological 
replicates each (Supplemental Figure S2, average Pearson correlation coefficient r = 0.54), we 
identified 4`513 proteins, of which we could quantify 3`778 by minimally two peptides 
(Supplemental Table S1). Fold changes comparing IAV infected versus untreated control cells 
were used to identify significantly regulated host cell proteins upon IAV treatment (Figure 1B, 
Supplemental Figure S3). In total, we identified 236 proteins, which exhibited a significantly 
changed abundance (Supplemental Table S2). Various proteins known to play a role in the 
“influenza A virus” life cycle were significantly enriched (KEGG, FDR=7.98e-05). Out of these 236 
candidates, 20 proteins were shown to interact with IAV proteins and to be critical for viral 
replication (7). Additionally, 20 proteins were also identified as being regulated by IAV in two other 
recent MS-based proteomics studies (9,10) (see Supplemental Table S3 for hits commonly 
identified by other studies).187 of the regulated proteins formed an interaction network based on 
STRING DB indicating a functional connection between regulated proteins after infection (Figure 
1C) (24). Amongst others, interacting proteins were significantly enriched in proteins of the “type 
I interferon signaling pathway” (GO BP, FDR=3.66e-20), such as IFN-induced IFIT1, IFIT2 and 
IFIT3, which belong to the same gene family, IFIT1 being known to act as a sensor for viral single-
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stranded RNA (26) (see Supplemental Tables S4-S7 for complete GO BP, MF, CC and KEGG 
enrichments).  
We validated increased abundance after IAV infection of three proteins by western blot (WB) and 
immunofluorescence (IF) analysis, which were so far not known to be regulated by IAV. The poly 
[ADP-ribose] polymerase transcription factor PARP14, which was described to be important for T 
cell differentiation into Th2, Th17 and Tfh cells (27,28), was shown by WB to be more abundant 
after virus infection (Figure 1D). Next to PARP14, we also identified PARP9, 10 and 12 as 
upregulated indicating a broader effect of IAV infection on this family of transcription factors 
(Supplementary Table S2). The increased abundance of the E3 ubiquitin ligase DTX3L involved 
in DNA damage responses was validated by IF (Figure 1E) (29). Finally, the E2 ubiquitin-
conjugating enzyme UBE2L6 was reproducibly identified as slightly upregulated by WB and IF 
(Figure 1D-E). UBE2L6 is the E2 enzyme of ISG15, which is known to be involved in the anti-IAV 
host response (30). Interestingly, also HERC5, the respective E3 enzyme, was identified as 
significantly enriched (Supplementary Table S2). Thus, IAV infection induced a potent host cell 
response affecting known (31) as well as new pathways potentially critical in anti-viral host cell 
signaling. 
 
IAV-induced changes in subcellular localization of host proteins  
In a comprehensive study addressing human cytomegalovirus, it was shown that viral proteins 
change the subcellular localization of numerous host cell proteins (32). To study the influence of 
IAV on subcellular protein localization, we performed experiments based on a PCP-SILAC setup 
(33). In a triple labeling approach, we fractionated IAV and untreated cells into vesicular, nuclear, 
mitochondrial and cytosolic compartments (Figure 2A). Light-labeled fractions were combined and 
served as an internal standard, spiked in a 1:1:1 ratio into mixed fractions of medium-heavy and 
heavy labeled cells. This allowed the generation of protein fractionation profiles by LC-MS/MS and 
the identification of IAV-induced changes in the subcellular localization of proteins (ratio 
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heavy/light over all compartments compared to ratio medium-heavy/light over all compartments). 
Average ratios of two biological replicates were used to generate 1`858 protein profiles 
(Supplemental Table S8), which were analyzed by fuzzy c-means clustering (Figure 2B) (21,22). 
Profiles separated into eight clusters of similar size and a GO term-enrichment analysis was 
performed to detect enriched protein groups in each cluster (Figure 2C). As expected, clusters 
and GO terms reflected the cell fractionation approach, e.g. cluster 1 and 2 protein profiles peak 
in the mitochondrial fraction, which is mirrored by the enriched GO terms.  
We identified four complexes/processes that changed subcellular localization due to IAV 
treatment: the proteasome regulatory complex, the MCM complex, translation initiation and 
elongation, and the ribosome (Figure 2C). Respective GO terms were enriched in clusters 7 and 
8 under control conditions and changed to clusters 3 and 7 upon IAV infection, respectively. The 
MCM complex, a DNA replicative helicase, appeared to shift from the nuclear to the vesicular 
fraction under infection (Figure 2D). Indeed, MS-based quantification of MCM proteins in the 
nuclear fraction revealed a significant decrease in IAV treated cells (Figure 2E), which was also 
observed by IF analysis of the subunit MCM7 (Figure 2F). This indicated a reduced ability of IAV 
infected cells to initiate host genome replication, potentially impairing cell proliferation. In parallel 
ribosomal proteins, as exemplified by fractionation profiles of large ribosomal subunit proteins 
(Figure 2G), appeared to be more abundant in the vesicular fraction upon IAV infection. WB 
analysis of the ribosomal protein RPL4 in the vesicular fraction confirmed a significant increase in 
IAV treated cells (Figure 2H, p<0.01, n=3). As the majority of changes in cellular configuration and 
organization of protein complexes seemed to occur in the vesicular fraction and IAV was shown 
to interfere with intracellular vesicle trafficking, in particular autophagy (15), we decided to focus 
further analyses on to the vesicular fraction.  
 
IAV-induced changes of the autophagosomal proteome   
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IAV was shown to interfere with lysosomal targeting of autophagosomes and to lead to 
autophagosome accumulation (for review see (14)). However, it is still under debate whether IAV 
infection blocks maturation or rather induces functional autophagy, which ultimately leads to an 
accumulation of autophagosomes (15,34). Before continuing the analysis of the vesicular 
proteome in IAV treated cells, we analyzed the consequences of IAV treatment on lysosomal 
targeting of autophagosomes in our experimental system. We used A549 cells stably expressing 
the autophagosomal marker protein MAP1LC3B (LC3-II) fused to GFP. Upon IAV treatment, we 
observed an accumulation of autophagosomes by IF to a similar extent as by blocking lysosomal 
acidification/degradation by concanamycin A (conA, Figure 3A). Next, we analyzed autophagy flux 
by WB comparing the band intensities of the autophagy receptor SQSTM1 and of LC3-II in the 
presence and absence of conA and IAV, respectively (Figure 3B-C) (35). In agreement with a 
block of autophagosomal-lysosomal fusion (15), we detected a decreased autophagy flux in our 
experimental conditions. Thus, IAV infection results in an autophagy block, an accumulation of 
autophagosomes and accordingly in an expansion of the vesicular compartment. 
To study the regulation of the vesicular proteome by IAV, again a PCP-SILAC-based approach 
was chosen (Figure 4A, Supplemental Tables S9-S10) (17,36). Cells were lysed by dounce 
homogenization, the vesicular fraction was enriched by differential centrifugation and separated 
by gradient centrifugation. Six fractions were collected and proteins therein analyzed by WB and 
LC-MS/MS. Protein gradient profiles of conA-treated cells, which leads to a block of constitutive 
autophagy, were compared to IAV treated cells. In agreement to published data, in both conditions 
autophagosomes were fractionated as described (15,36), and as controlled by WB analysis of 
GFP-linked LC3-II (Figure 4B). Corroborating the finding that IAV localizes to autophagosomes 
(15), we identified all viral proteins as co-migrating with the autophagosomal marker proteins LC3 
and GABARAPL (Figure 4C). To study vesicular proteomes unbiasedly, protein profiles were 
again clustered and the potential autophagosomal cluster was identified by known marker proteins 
(LC3, GABARAPL, SQSTM1; Supplemental Figure S4, n=2). In IAV treated cells, 
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autophagosomes appeared to be more heterogeneous, as marker proteins spread over two 
related clusters. A GO term enrichment analysis of potential autophagosomal proteins was 
performed, clearly discriminating the two treatments (Figure 4D). Whereas in conA-treated cells 
autophagosomes appeared to contain mostly lysosomal and endosomal proteins, IAV treatment 
led to an accumulation of ribosomal proteins and proteins involved in viral infection in 
autophagosomal clusters.  
 
IAV-induced accumulation of ribosomes inside autophagosomes 
As GO term enrichment analysis indicated a virus-dependent, increased localization of ribosomal 
proteins within autophagosomes, we studied a potential ribosome-autophagosome crosstalk in 
IAV treated cells. Indeed, in contrast to conA-treated cells, proteins of the large ribosomal subunit 
closely followed autophagosomal marker proteins in gradient centrifugations of IAV treated cells 
(Figure 5A). Co-migration in gradient centrifugations could mean both, association with or uptake 
by autophagosomes. This question was addressed biochemically using a proteinase K protection 
assay (37), which enables the discrimination between truly (intra)organellar proteins and 
associated proteins not inside vesicles by performing digestion assays in the absence and 
presence of detergent (Figure 5B). Whereas soluble GFP-LC3-I was degraded by proteinase K in 
the presence and absence of detergent, the autophagy receptor SQSTM1 and membrane-bound 
GFP-LC3-II, both mainly localizing inside autophagosomes, were protease resistant in the 
absence of detergent. Under control conditions, a minor protease resistant band of the ribosomal 
protein RPL4 was detected. However, this was similar to the observed GFP-LC3-I bands indicating 
that under control conditions ribosomes might only co-migrate with autophagosomes, in 
agreement with earlier studies (36). Under IAV infection, autophagosomes appeared to be more 
fragile, as partial digestion of GFP-LC3-II and SQSTM1 could be observed in the absence of 
detergent (Figure 5B). Importantly however, RPL4 was relatively protease resistant in the absence 
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of detergent, leading to a significant increase of the ribosomal protein inside autophagosomes 
under IAV treatment (Figure 5C).  
To test if in addition to viral proteins and ribosomes, viral mRNA could be a cargo of 
autophagosomes, RNA was isolated from gradient fractions. Primers for mRNA encoding viral M1 
and NS1 and for the human housekeeping genes 18S and HPRT1 were used to determine the 
mRNA content of the vesicular gradient fractions by PCR (Figure 5D). Whereas it was not possible 
to detect mRNA of the human housekeeping genes (data not shown), viral mRNA showed a similar 
gradient profile as viral proteins. Thus, in addition to ribosomes and viral proteins, viral mRNA 
appeared to localize to autophagosomes.  
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Discussion 
As IAV infects epithelial cells of the lung (38), we used the lung epithelial cancer cell line A549 to 
study the response of the host cell proteome to IAV infection. We analyzed protein abundance 
changes as well as IAV-induced changes in subcellular protein localization, identifying pleiotropic 
effects and shedding light on processes so far not known to be regulated by IAV. 
We could show that IAV positively regulated the abundance of proteins involved in the class I IFN 
response, corroborating literature knowledge (39). Importantly, we also characterized so far 
unknown molecular details. Whereas the antiviral effects of the ubiquitin-like modifier ISG15 were 
well known (30,40), we could show that the respective E2 enzyme UBE2L6 and the E3 ligase 
HERC5 were upregulated on protein level, potentially being causative for the increased 
modification of viral NS1 by ISG15. Upon IAV treatment, we also identified increased abundance 
of the transcription factors PARP9, 10, 12 and 14, which belong to the same family of 
macroPAMPs (pathogen-associated molecular patterns) and are implicated in immune activation. 
The expression of PARP9 was shown to be induced by IFNγ, which is also triggered by IAV, and 
expression of PARP9 in lymphoma cells was found to increase the expression of several 
interferon-stimulated genes (41). PARP14 is involved in the transcriptional activation of the IL4 
gene and may promote an inflammatory response. To our knowledge, both PARP9 and 14 were 
so far not found to be upregulated by virus infection. PARP9 and the E3 ubiquitin-protein ligase 
DTX3L, which was also identified as increased, are located in a head-to-head orientation on 
chromosome 3q21 and are regulated by an IFNγ-responsive bidirectional promoter (42). DTX3L 
binds to PARP9 and regulates its subcellular localization, highlighting a coordinated, IAV-
dependent expression of PARP9 and DTX3L in A549 cells.  
Next to changes in protein abundance, IAV also affected the subcellular localization of host 
proteins. Whereas MS-based proteomics approaches were used in the past to study the effects 
of influenza virus on organellar proteomes, amongst others nucleus, nucleolus, mitochondrion and 
cytosol (43-45), a detailed analysis on the underlying dynamics was missing. To our knowledge, 
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this is the first attempt to globally analyze IAV-induced changes in cellular protein localization. The 
majority of changes in cellular reorganization of protein complexes seemed to affect the vesicular 
fraction, possibly highlighting the block of autophagosomal maturation by IAV (15). We could show 
that the MCM complex was less abundant in nuclei of IAV infected cells and appeared to 
accumulate in the vesicular fraction. It was shown that the MCM complex is important for viral 
replication stabilizing the replication polymerase complex by promoting the interaction between 
influenza polymerase and nascent cRNA (46). However, this complex was thought to form inside 
nuclei. Our data raises the question if this complex could be exported from the nucleus by vRNPs, 
and also play a role in vesicles? 
A second complex, which appeared to accumulate in the vesicular fraction upon IAV treatment, 
was the ribosome. As both, IAV and ribosomal proteins may localize to autophagosomes 
(15,47,48), we analyzed autophagy and autophagosomal protein content in IAV treated cells in 
detail. In the chosen experimental system, IAV blocked autophagosome maturation and hence we 
compared autophagosomes accumulation following IAV infection to autophagosomes 
accumulated by conA treatment, representing autophagosomes under basal conditions (36). 
Autophagosomes appeared to be more heterogeneous and fragile under IAV treatment as 
indicated by gradient profiles of respective marker proteins and decreased stability in protease 
protection assays. This could be due to the fact that IAV leads to a redirection of autophagic 
membranes to the plasma membrane and the site of IAV budding (16). We biochemically 
characterized that ribosomal proteins are inside autophagosomes upon IAV treatment, and that 
viral mRNA appears to be taken up by autophagosomes as well. Together with the localization of 
viral proteins inside autophagosomes (15), this opens up the possibility that active viral protein 
biosynthesis might happen inside autophagosomes. Whether this is of physiological importance 
remains elusive. Whereas it has been reported by several laboratories that autophagy 
incompetent cells produce less viral proteins, an effect on viral titer was not found (15,49). 
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However, recently a time-dependent effect of autophagy levels on IAV titer was described (50). 
Our findings could highlight the cell biological reasons for these phenotypic observations.  
Taken together, by a comprehensive MS-based proteomics approach we identified IAV-
dependent changes in host cell protein abundances as well as localizations, and characterized 
the autophagosome as a potential organelle in which viral protein translation may take place. 
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Figure Legends 
 
Figure 1. IAV-induced changes of the host cell proteome. (A) SILAC labeled A549 cells were 
IAV infected for 24 h with a MOI of 2 or left untreated. Cells were either lysed (whole cell lysate 
(WCL)) or fractionated into cytosol, mitochondria, nuclei and vesicles. Lysates and fractions were 
mixed in a ratio of 1:1, respectively, and samples were prepared for MS analysis as outlined. All 
experiments were performed in two biological replicates with reversed labels. (B) Ratios of two 
biological replicates of WCL analyses were averaged and used to highlight IAV-regulated proteins. 
Grey dots represent unaffected proteins. Red dots represent proteins that significantly changed 
abundance upon IAV treatment (significance B, p<0.05, BH corrected). (C) STRING interaction 
network of significantly changed proteins in WCL and cellular compartments. Red marked proteins 
carry GO BP term “type I interferon signaling pathway”, yellow marked proteins carry KEGG term 
“Influenza A”. (D) A549 cells were either left untreated or infected with IAV for 24 h with a MOI of 
2. Samples were analyzed by western blot with indicated antibodies. Actin served as loading 
control. (E) Immunofluorescence staining of untreated and IAV-treated A549 cells (MOI=4) for 
DTX3L and UBE2L6 (green), respectively, and DAPI (blue). Scale bars represent 10 µm.  
 
Figure 2. IAV-induced changes of subcellular localizations of host proteins. (A) SILAC-work 
flow of cell fractionation analysis. SILAC-labeled A549 cells were IAV infected for 24 h 
(Arg10/Lys8) with a MOI of 2 or left untreated (Arg6/Lys4 and Arg0/Lys0). All labels were 
separated into nuclear, mitochondrial, cytosolic and vesicular fractions. The light labeled fractions 
were combined and the protein concentration of all fractions and all labels was determined. The 
separated fractions of untreated and infected cells were mixed in a 1:1 ratio and the same amount 
of the combined light fraction was spiked in as an internal standard. Samples were prepared for 
MS analysis as outlined. (B) Protein profiles of two biological replicates each were merged, 
standardized and clustered using the fuzzy c-means algorithm. Profiles separated into 8 clusters. 
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Color scale represents cluster membership values. (C) GO CC term enrichment analysis was used 
to detect enriched protein groups in respective clusters comparing IAV and untreated cells. Blue 
color represents unchanged enriched protein groups in the respective clusters, whereas changes 
are shown in red. (D) IAV-induced changes in the cellular localization of the MCM protein complex. 
Profiles of the 6 members of the MCM complex over the 4 compartments under the two different 
treatments are shown (standardized SILAC ratios). (E) Average nuclear SILAC ratios of MCM 
proteins compared to the internal standard are shown from untreated and infected cells resulting 
in a significant difference (*: p<0.05). Bars represent standard deviation. (F) Average nuclear 
intensity of MCM7 in untreated and infected cells as analyzed by IF analysis (***: p<0.001). (G) 
IAV-induced changes in the cellular localization of ribosomes. Gray lines represent the 
standardized SILAC profiles of all detected ribosomal proteins of the large ribosomal subunit 
(RPL). Black lines illustrate the average profiles. (H) Vesicular RPL4 intensity of untreated and 
infected cells as analyzed by western blot (n=3, **: p<0.01). Bars represent standard deviation. 
 
Figure 3. IAV blocks functional autophagy. A549 GFP-LC3 cells were either left untreated, 
infected with IAV for 24 h (MOI = 2), treated for 7 h with 2 nM concanamycin A (conA), or infected 
for 24 h and treated for the last 7 h with 2 nM conA. (A) Immunofluorescence of untreated, conA 
treated and IAV infected A549 GFP-LC3 cells. The green dots represent autophagosomes, 
nuclear DAPI-staining is shown in blue. Scale bar represents 10 µm. (B) Immunoblot analysis of 
indicated host proteins of untreated, conA treated, IAV infected and IAV infected and conA treated 
A549 GFP-LC3 cells. GAPDH served as a loading control. (C) Level of autophagic flux of 
untreated and infected cells. The measured intensity of LC3-II was normalized to GAPDH and the 
relative autophagic flux was calculated by dividing LC3-II intensities of samples with conA by 
respective intensities without conA. Data of two biological replicates are shown relative to ctrl 
experiments.  
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Figure 4. IAV localizes to autophagosomes and changes the autophagosomal proteome. 
(A) PCP-SILAC workflow of isolation of autophagosomes via density gradient centrifugation. 
SILAC labeled cells were dounced and the vesicular fraction was applied on self-made iodixanol 
gradients for gradient centrifugation. Six fractions were collected and the light labeled fractions 
were mixed together and applied in a 1:1 ratio as an internal standard to the collected fractions of 
the heavy label. The combined samples were separated by SDS-PAGE, in-gel digested by trypsin, 
and analyzed by LC-MS/MS. (B) Western blot analysis of the autophagosomal marker protein 
LC3-II. Black bars indicate quantification. (C) Gradient profiles of viral and autophagosomal 
marker proteins. The gray lines represent the gradient distribution profile of all detected viral 
proteins. LC3 and GABARAPL indicate the distribution of autophagosomes over the gradient. (D) 
GO term enrichment of the autophagosomal clusters (AC) of conA and IAV treated cells. Content 
of AC of IAV and conA treated cells were analyzed with Perseus for enriched GO terms. A 
selection of enriched GO terms is shown and the number of proteins assigned to each particular 
GO term is shown in percent (p<0.01, BH corrected, minimum number of proteins in each category 
for enriched GO terms were 5).  
 
Figure 5. IAV infections leads to localization of ribosomes and viral mRNA to 
autophagosomes. (A) Gradient profiles of ribosomal and autophagosomal marker proteins. The 
gray lines represent the gradient distribution profiles of all detected ribosomal proteins of the large 
subunit (RPL) of the corresponding treatment. LC3 and GABARAPL indicate the distribution of 
autophagosomes over the gradient. (B) Proteinase K protection assay. A549 GFP-LC3 cells were 
either stimulated with conA for 7 h or infected with IAV for 24 h. After differential centrifugation, 
the vesicular fraction was used for the protease protection assay. Shown are two biological 
replicates each. SQSTM1, RPL4 and LC3 were detected via western blot. (C) The RPL4 intensity 
was quantified relative to SQSTM1 and GFP-LC3-II (n=6). Error bars represent standard 
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deviations. (D) mRNA content of autophagosomes. mRNA was purified from the combined 
vesicular gradient fractions 2 and 3, 4 and 5, 6 and 7, respectively.  
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